Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q3 2021
Holdings as of Sep 30, 2021, filed Nov 15, 2021. Long positions only; changes compare share counts with Q2 2021.
- Positions
- 29
- 0 vs. Q2 2021
- Portfolio value
- $379.3M
- +$92.3M (+32.1%) vs. Q2 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 2,750,137 | $44.7M | 11.8% | +1,001,896+57.3% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 2,190,291 | $39.4M | 10.4% | +521,304+31.2% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 796,578 | $28.5M | 7.5% | +92,261+13.1% | Added | History |
| DRNADicerna Pharmaceuticals Inc | COM | 1,292,251 | $26.1M | 6.9% | +1,292,251 | New | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 481,094 | $21.5M | 5.7% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 999,433 | $18.7M | 4.9% | +377,940+60.8% | Added | History |
| CELCCelcuity Inc. | COM | 920,464 | $16.6M | 4.4% | +49,497+5.7% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 1,912,511 | $16.1M | 4.2% | +544,929+39.8% | Added | History |
| MRUSMerus N.V. | COM | 718,136 | $15.8M | 4.2% | +718,136 | New | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 4,169,896 | $15.2M | 4.0% | +640,431+18.1% | Added | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 3,118,761 | $14.5M | 3.8% | +22,032+0.7% | Added | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 5,123,509 | $14.0M | 3.7% | +1,792,194+53.8% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 248,207 | $13.4M | 3.5% | −75,230−23.3% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 667,674 | $11.0M | 2.9% | +481,269+258.2% | Added | History |
| TNYATenaya Therapeutics, Inc. | COM | 513,930 | $10.6M | 2.8% | +513,930 | New | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 362,869 | $8.95M | 2.4% | +362,869 | New | History |
| XENEXenon Pharmaceuticals Inc. | COM | 579,432 | $8.85M | 2.3% | +253,096+77.6% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 498,079 | $8.83M | 2.3% | +287,479+136.5% | Added | History |
| KRONKronos Bio, Inc. | COM | 298,839 | $6.26M | 1.7% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 226,228 | $6.22M | 1.6% | +226,228 | New | History |
| GNCAGenocea Biosciences, Inc. | COM NEW | 3,079,756 | $5.91M | 1.6% | +150,309+5.1% | Added | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 312,553 | $5.45M | 1.4% | +85,882+37.9% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 305,125 | $4.96M | 1.3% | 00.0% | Unchanged | History |
| MREOMereo BioPharma Group plc | SPON ADS | 1,972,958 | $4.78M | 1.3% | −86,771−4.2% | Reduced | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 125,000 | $3.73M | 1.0% | 00.0% | Unchanged | History |
| IVAInventiva S.A. | ADS | 262,658 | $3.72M | 1.0% | 00.0% | Unchanged | History |
| BCLS Acquisition CorpG0904B105 | COM CL A | 250,000 | $2.49M | 0.7% | 00.0% | Unchanged | – |
| ATXSAstria Therapeutics, Inc. | COM | 239,270 | $2.12M | 0.6% | +239,270 | New | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 97,143 | $969.0K | 0.3% | 00.0% | Unchanged | History |
Sold out since Q2 2021 (6)
Positions held at the end of Q2 2021 that are gone from this filing.
| Security | Class | Shares in Q2 2021 | Value in Q2 2021 | % of portfolio in Q2 2021 | History |
|---|---|---|---|---|---|
| CNSTConstellation Pharmaceuticals Inc | COM | 440,869 | $14.9M | 5.2% | History |
| MGNXMacrogenics Inc | COM | 393,850 | $10.6M | 3.7% | History |
| EPIXESSA Pharma Inc. | COM NEW | 281,911 | $8.05M | 2.8% | History |
| MRSNMersana Therapeutics, Inc. | COM | 429,228 | $5.83M | 2.0% | History |
| MCRBSeres Therapeutics, Inc. | COM | 145,453 | $3.47M | 1.2% | History |
| Catabasis Pharmaceuticals IN14875P206 | COM NEW | 1,617,000 | $3.41M | 1.2% | – |